MétaCan
Menu
← Back to cohort
Record W4308259598 · doi:10.1101/2022.11.04.22281891

The projected prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030

2022· preprint· en· W4308259598 on OpenAlexafffund
Keri N. Althoff, Cameron Stewart, Elizabeth Humes, Lucas Gerace, Cynthia M. Boyd, Kelly A. Gebo, Amy C. Justice, Emily P. Hyle, Sally B. Coburn, Raynell Lang, Michael J. Silverberg, Michael A. Horberg, Viviane D. Lima, M. John Gill, Maile Karris, Peter F. Rebeiro, Jennifer E. Thorne, Ashleigh J. Rich, Heidi Crane, Mari M. Kitahata, Anna Rubtsova, Cherise Wong, Sean X. Leng, Vincent C Marconi, Gypsyamber DʼSouza, Hyang Nina Kim, Sonia Napravnik, Kathleen A. McGinnis, Gregory D. Kirk, Timothy R. Sterling, Richard D Moore, Parastu Kasaie

Bibliographic record

VenuemedRxiv · 2022
Typepreprint
Languageen
FieldMedicine
TopicHIV-related health complications and treatments
Canadian institutionsAIDS VancouverUniversity of Calgary
FundersNational Institute of Diabetes and Digestive and Kidney DiseasesNational Institute of Allergy and Infectious DiseasesNational Institute of Neurological Disorders and StrokeNational Institute of Nursing ResearchNational Institute on Deafness and Other Communication DisordersNational Institute on Drug AbuseNational Institute of Mental HealthNational Heart, Lung, and Blood InstituteNational Institute on AgingNational Cancer InstituteNational Institute on Alcohol Abuse and AlcoholismNational Human Genome Research InstituteHealth Resources and Services AdministrationNational Institute of Dental and Craniofacial ResearchCenters for Disease Control and PreventionGovernment of AlbertaAgency for Healthcare Research and QualityNational Institutes of HealthCanadian Institutes of Health ResearchRegeneron Pharmaceuticals
KeywordsMedicineDyslipidemiaDepression (economics)AnxietyComorbidityDiabetes mellitusMen who have sex with menGerontologyDiseaseHuman immunodeficiency virus (HIV)DemographyPsychiatryInternal medicineFamily medicineEndocrinology

Abstract

fetched live from OpenAlex

ABSTRACT Importance Estimating the medical complexity of people aging with HIV can inform clinical programs and policy to meet future healthcare needs. Objective To project the prevalence of comorbidities and multimorbidity among people with HIV (PWH) using antiretroviral therapy (ART) in the US through 2030. Design Agent-based simulation model Setting HIV clinics in the United States in the recent past (2020) and near future (2030) Participants In 2020, 674,531 PWH were using ART; 9% were men and 4% women with history of injection drug use; 60% were men who have sex with men (MSM); 8% were heterosexual men and 19% heterosexual women; 44% were non-Hispanic Black/African American (Black); 32% were non-Hispanic White (White); and 23% were Hispanic. Exposure(s) Demographic and HIV acquisition risk subgroups Main Outcomes and Measures Projected prevalence of anxiety, depression, stage ≥3 chronic kidney disease (CKD), dyslipidemia, diabetes, hypertension, cancer, end-stage liver disease (ESLD), myocardial infarction (MI), and multimorbidity (≥2 mental or physical comorbidities, other than HIV). Results We projected 914,738 PWH using ART in the US in 2030. Multimorbidity increased from 58% in 2020 to 63% in 2030. The prevalence of depression and/or anxiety was high and increased from 60% in 2020 to 64% in 2030. Hypertension and dyslipidemia decreased, diabetes and CKD increased, MI increased steeply, but there was little change in cancer and ESLD. Among Black women with history of injection drug use (oldest demographic subgroup in 2030), CKD, anxiety, hypertension, and depression were most prevalent and 93% were multimorbid. Among Black MSM (youngest demographic subgroup in 2030), depression was highly prevalent, followed by hypertension and 48% were multimorbid. Comparatively, 67% of White MSM were multimorbid in 2030 (median age in 2030=59 years) and anxiety, depression, dyslipidemia, CKD, and hypertension were highly prevalent. Conclusion and relevance The distribution of multimorbidity will continue to differ by race/ethnicity, gender, and HIV acquisition risk subgroups, and be influenced by age and risk factor distributions that reflect the impact of social disparities of the health on women, people of color, and people who use drugs. HIV clinical care models and funding are urgently required to meet the healthcare needs of people with HIV in the next decade. KEY POINTS Question How will the prevalence of multimorbidity change among people with HIV (PWH) using antiretroviral therapy in the US from 2020 to 2030? Findings In this agent-based simulation study using data from the NA-ACCORD and the CDC, multimorbidity (≥2 mental/physical comorbidities other than HIV) will increase from 58% in 2020 to 63% in 2030. The composition of comorbidities among multimorbid PWH vary by race/ethnicity, gender, and HIV acquisition risk group. Meaning HIV clinical programs and policy makers must act now to identify resources and care models to meet the increasingly complex medical needs of PWH over time, particularly mental healthcare needs.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Simulation or modeling · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.058
Threshold uncertainty score0.114

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.042
GPT teacher head0.329
Teacher spread0.287 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSimulation or modeling
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2022
Admission routes2
Has abstractyes

Explore more

Same venuemedRxiv→Same topicHIV-related health complications and treatments→French-language works237,207→